Iris Acquisition II Targets $150M IPO, Faces Dilution Concerns

TL;DR

**Avoid IRAB-UN; the massive dilution from founder shares and potential conflicts of interest make this SPAC a high-risk gamble for public investors.**

AI Summary

Iris Acquisition Corp II (IRAB-UN) filed an S-1/A on October 3, 2025, for an initial public offering of 15,000,000 units at $10.00 each, aiming to raise $150,000,000. Each unit comprises one Class A ordinary share and one-half of one redeemable warrant. The company, a newly organized SPAC, has not yet identified a business combination target, focusing on organizational activities. Its sponsor, Iris Acquisition Holdings II LLC, will purchase 372,500 private placement units for $3,725,000, and Cohen & Company Capital Markets will purchase 150,000 private placement units for $1,500,000. The sponsor initially acquired 5,750,000 Class B ordinary shares for a nominal $25,000, or $0.00435 per share, which could lead to significant dilution for public shareholders. The company will repay up to $300,000 in sponsor loans and pay a $20,000 monthly administrative fee to the sponsor. Public shareholders face dilution from founder shares, private placement units, and warrant exercises, with potential conflicts of interest due to the sponsor's low cost basis and management's existing obligations.

Why It Matters

This S-1/A filing signals Iris Acquisition Corp II's intent to raise $150 million, providing a new SPAC vehicle for a private company to go public. For investors, the significant dilution from founder shares purchased at $0.00435 per share and the potential for conflicts of interest due to management's low cost basis are critical considerations. Employees and customers of a future target company will be impacted by the public listing and the SPAC's strategic direction. In the competitive SPAC market, Iris Acquisition II's generalist approach and focus on mid-market companies will need to differentiate itself amidst numerous blank-check firms.

Risk Assessment

Risk Level: high — The risk level is high due to the significant dilution potential from the sponsor's 5,750,000 founder shares purchased for a nominal $25,000, or $0.00435 per share, compared to the public offering price of $10.00 per unit. This creates a strong incentive for the sponsor to complete a business combination even if it's not optimal for public shareholders. Additionally, the filing explicitly states that officers and directors may have fiduciary obligations to other entities, creating material conflicts of interest.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the substantial dilution and potential conflicts of interest before considering an investment in IRAB-UN. Given the low cost basis of founder shares and the administrative fees, it is prudent to wait until a definitive business combination target is announced and its terms are fully disclosed to assess the true value proposition.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

$0

net Income

$0

eps

$0.00

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $150,000,000 — Gross proceeds from IPO (Targeted capital raise from 15,000,000 units at $10.00 each)
• 15,000,000 — Public units offered (Number of units available in the initial public offering)
• $10.00 — Offering price per unit (Price for each unit in the IPO)
• 5,750,000 — Class B ordinary shares (Founder shares purchased by the sponsor)
• $0.00435 — Purchase price per founder share (Nominal price paid by the sponsor for Class B ordinary shares)
• $25,000 — Aggregate purchase price for founder shares (Total amount paid by the sponsor for 5,750,000 Class B shares)
• 372,500 — Private placement units (Sponsor) (Units to be purchased by Iris Acquisition Holdings II LLC)
• $3,725,000 — Aggregate private placement (Sponsor) (Total investment by the sponsor in private placement units)
• $20,000 — Monthly Administrative Services Fee (Amount paid to the sponsor for administrative support)
• 24 months — Completion window for business combination (Timeframe to complete an initial business combination from closing of offering)

Key Players & Entities

• Iris Acquisition Corp II (company) — Registrant and SPAC
• Iris Acquisition Holdings II LLC (company) — Sponsor of the SPAC
• Sumit Mehta (person) — Chief Executive Officer of Iris Acquisition Corp II
• Cohen & Company Capital Markets (company) — Underwriter and private placement purchaser
• Loeb & Loeb LLP (company) — Legal counsel
• Forbes Hare (company) — Legal counsel
• Ropes & Gray LLP (company) — Legal counsel
• SEC (regulator) — Securities and Exchange Commission
• Nasdaq Stock Market LLC (company) — Intended listing exchange
• Cayman Islands (regulator) — Jurisdiction of incorporation

FAQ

Risk Factors

• Dilution from Sponsor Shares and Warrants [high — financial]: The sponsor acquired 5,750,000 Class B ordinary shares for a nominal $25,000, or $0.00435 per share. These founder shares are convertible into Class A ordinary shares and represent a significant stake. Additionally, the sponsor and underwriters are purchasing private placement units, and all warrants (public and private) are exercisable, leading to substantial potential dilution for public shareholders.
• Lack of Identified Business Combination Target [high — operational]: Iris Acquisition Corp II is a newly organized SPAC with no identified business combination target. Its efforts to date have been limited to organizational activities and preparing for this offering. The company has a 24-month completion window to identify and complete a business combination, creating a time-sensitive risk.
• Sponsor Loan Repayment and Administrative Fees [medium — financial]: The company will repay up to $300,000 in sponsor loans and pay a $20,000 monthly administrative fee to the sponsor. These ongoing costs reduce the capital available for the business combination and can impact the net proceeds available to shareholders.
• Redemption Risk and Potential for Low Net Tangible Assets [high — financial]: Public shareholders can redeem their shares at the IPO price ($10.00) upon a business combination, regardless of their vote. The company's charter does not have a minimum net tangible asset requirement, meaning a significant portion of the IPO proceeds could be redeemed, leaving insufficient capital for a viable business combination.
• Potential Conflicts of Interest [medium — legal]: The sponsor's low cost basis in founder shares and potential for significant profits from the IPO and subsequent business combination may create conflicts of interest. Management's existing obligations and potential compensation structures could also influence decision-making.

Industry Context

The Special Purpose Acquisition Company (SPAC) market has seen significant activity, offering a faster route to public markets for target companies compared to traditional IPOs. However, increased regulatory scrutiny and a higher failure rate for SPACs post-combination have led to a more cautious investor sentiment. The market is characterized by a wide range of SPACs targeting various sectors and geographies, with success often depending on the sponsor's reputation, deal execution capabilities, and the quality of the target business.

Regulatory Implications

As a SPAC, Iris Acquisition Corp II is subject to SEC regulations governing public offerings and ongoing reporting requirements. The structure of SPACs, including the role of sponsor shares, warrants, and redemption rights, has attracted increased attention from regulators, potentially leading to stricter disclosure requirements or changes in SPAC-related rules.

What Investors Should Do

1. Analyze Dilution Impact
2. Evaluate Sponsor Alignment and Track Record
3. Monitor Target Identification and Deal Terms
4. Consider Redemption Rights

Key Dates

• 2025-10-03: Filing of S-1/A Amendment No. 2 — Provides updated details for the initial public offering, including unit structure, private placement details, and risk factors.
• 2025-07-15: Sponsor Purchase of Founder Shares — The sponsor acquired 5,750,000 Class B ordinary shares for $25,000, establishing their initial stake and potential for dilution.

Glossary

SPAC

A Special Purpose Acquisition Company is a shell company that is created to raise capital through an initial public offering (IPO) for the purpose of acquiring an existing company. (Iris Acquisition Corp II is a newly organized SPAC seeking a business combination.)

Units

In a SPAC IPO, units typically consist of one Class A ordinary share and a fraction of a redeemable warrant. (Iris Acquisition Corp II is offering 15,000,000 units, each comprising one share and one-half warrant.)

Redeemable Warrants

These give the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. They are often included in SPAC units. (Each unit includes one-half of a redeemable warrant, exercisable at $11.50 per share.)

Founder Shares

Shares typically purchased by the SPAC's sponsor or management team at a nominal price before the IPO, often convertible into Class A shares and subject to vesting or dilution adjustments. (The sponsor holds 5,750,000 founder shares acquired for $0.00435 each, which are subject to conversion and anti-dilution provisions.)

Private Placement Units

Units purchased by the SPAC's sponsor and/or underwriters simultaneously with the IPO, typically at the IPO price, to provide additional capital and align interests. (The sponsor and underwriters are purchasing private placement units for $10.00 each.)

Trust Account

A segregated account where the proceeds from the IPO are held until a business combination is completed or the SPAC liquidates. (Proceeds from the IPO, excluding certain fees and a portion of private placement proceeds, will be deposited into a trust account.)

Business Combination

The merger, acquisition, or other transaction through which a SPAC combines with an operating company. (Iris Acquisition Corp II is seeking to complete an initial business combination within 24 months.)

Year-Over-Year Comparison

This is the initial public offering registration statement (S-1/A Amendment No. 2), so there are no prior year financial metrics to compare against. The filing details the structure of the offering, including the number of units, price, and components (shares and warrants). Key information presented includes the sponsor's significant stake in founder shares and private placement units, potential dilution, and the company's objective to find a business combination target within 24 months.

Key Financial Figures

• $150,000,000 — TO COMPLETION, DATED OCTOBER 3, 2025 $150,000,000 Iris Acquisition Corp II 15,000,000
• $10.00 — 5,000,000 units at an offering price of $10.00 each. Each unit consists of one Class A
• $11.50 — ne Class A ordinary share at a price of $11.50 per share, subject to adjustment as des
• $5,000,001 — t tangible asset condition, such as the $5,000,001 net tangible asset requirement. As such
• $3,725,000 — e of $10.00 per private placement unit ($3,725,000 in the aggregate (including if the over
• $1,500,000 — in full) at a price of $10.00 per unit ($1,500,000 in the aggregate (or $1,950,000 if the
• $1,950,000 — r unit ($1,500,000 in the aggregate (or $1,950,000 if the over-allotment is exercised in f
• $300,000 — ring or thereafter, we will repay up to $300,000 in loans made to us by our Sponsor to c
• $20,000 — s, and we will begin paying our Sponsor $20,000 per month (the "Administrative Services
• $100,000 — shall be net of taxes payable and up to $100,000 of interest to pay dissolution expenses
• $0.20 — (1) $ 141,000,000 (1) Includes (A) $0.20 per unit sold in the offering, or 2.0%
• $3,000,000 — the gross proceeds of the offering, or $3,000,000 in the aggregate (or $3,450,000 if the
• $3,450,000 — ing, or $3,000,000 in the aggregate (or $3,450,000 if the underwriters' over-allotment opt
• $0.075 — ion is exercised in full), of which (i) $0.075 per unit sold in the offering, excludin
• $1,125,000 — underwriter's over-allotment option, or $1,125,000, will be paid to the underwriters in ca

Filing Documents

• iac2s1a2092425.htm (S-1/A) — 2379KB
• iac2ex3-1i.htm (EX-3.1I) — 19KB
• iac2ex3-1ii.htm (EX-3.1II) — 265KB
• iac2ex4-4.htm (EX-4.4) — 129KB
• iac2ex10-1.htm (EX-10.1) — 42KB
• iac2ex10-2.htm (EX-10.2) — 75KB
• iac2ex10-3.htm (EX-10.3) — 102KB
• iac2ex10-4.htm (EX-10.4) — 51KB
• iac2ex10-5.htm (EX-10.5) — 58KB
• iac2ex10-6.htm (EX-10.6) — 98KB
• iac2ex10-7.htm (EX-10.7) — 11KB
• iac2ex14-1.htm (EX-14.1) — 37KB
• iac2ex23-1.htm (EX-23.1) — 2KB
• iac2ex99-1.htm (EX-99.1) — 22KB
• iac2ex99-2.htm (EX-99.2) — 23KB
• ex3-1i_01.jpg (GRAPHIC) — 19KB
• ex3-1ii_01.jpg (GRAPHIC) — 19KB
• 0001185185-25-001381.txt ( ) — 5397KB
• irab-20251003.xsd (EX-101.SCH) — 9KB
• irab-20251003_def.xml (EX-101.DEF) — 16KB
• irab-20251003_lab.xml (EX-101.LAB) — 123KB
• irab-20251003_pre.xml (EX-101.PRE) — 72KB
• iac2s1a2092425_htm.xml (XML) — 439KB

Underwriting

Underwriting Discount (1) Proceeds, Before Expenses, to us Per Unit $ 10.00 $ 0.60 (1) $ 9.40 Total $ 150,000,000 $ 9,000,000 (1) $ 141,000,000 (1) Includes (A) $0.20 per unit sold in the offering, or 2.0% of the gross proceeds of the offering, or $3,000,000 in the aggregate (or $3,450,000 if the underwriters' over-allotment option is exercised in full), of which (i) $0.075 per unit sold in the offering, excluding any units sold pursuant to the exercise of the underwriter's over-allotment option, or $1,125,000, will be paid to the underwriters in cash; (ii) $0.025 per unit sold in the offering, excluding any units sold pursuant to the exercise of the underwriter's over-allotment option, or up to $375,000 in the aggregate is payable to the underwriters in this offering upon execution of an agreement for an initial business combination, and (iii) $1,500,000 (or $1,950,000 of the underwriters' over-allotment is exercised in full) in the aggregate which will be invested by the underwriter to purchase 150,000 private placement units (or 195,000 private placement units if the over-allotment option is exercised in full) at $10.00 per unit and (B) $0.40 per unit sold in this offering, or 4.0% of the gross proceeds of the offering, or $6,000,000 in the aggregate (or up to $6,900,000 in the aggregate if the underwriters' over-allotment option is exercised in full) payable to the underwriters for deferred underwriting commissions to be deposited in a trust account located in the United States and released to the underwriters only upon the completion of an initial business combination, such fee to be proportionately reduced based on the amount of funds remaining in the trust account after redemptions. See "Underwriting" for additional information regarding underwriting compensation. Of the proceeds we receive from this offering and the sale of the private placement units, $150,000,000 or $172,500,000 if the underwriters' over- allotment option is exercised in

View Full Filing

View this S-1/A filing on SEC EDGAR